Exenatide: incretin therapy for patients with Type 2 diabetes mellitus

Volume: 3, Issue: 6, Pages: 671 - 690
Published: Nov 1, 2008
Abstract
Exenatide is the first in a novel class of drugs that mimics naturally occurring glucagon-like peptide 1. In patients with Type 2 diabetes mellitus (T2DM), control of both glycemia and bodyweight are important to minimize the risk of diabetes complications. Exenatide improves glycemic control through glucose-dependent insulin secretion, suppression of glucagon secretion, delaying gastric emptying and suppressing appetite. Exenatide therapy...
Paper Details
Title
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Published Date
Nov 1, 2008
Volume
3
Issue
6
Pages
671 - 690
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.